Chart Illustrates Efforts by CMS to Commoditize Molecular Diagnostic Testing
March 1, 2013 |
1 min read
The following chart helps to demonstrate how fees under the Palmetto Tier 1 and Tier 2 molecular fee schedules stack up against average fees under stacked coding for the higher volume tests. The trend clearly shows a push to move the price point for most genetic testing services below $200 and commoditize diverse and high complexity molecular diagnostic services.
XiFin is tracking published MAC allowed amounts, see the list here
SOURCE: 2012 comparison analysis provided by XiFin to chart plotting 2013 rates prepared by an industry consultant – March 21, 2013